Pyng Medical Corp.

Pyng Medical Corp.

September 12, 2007 11:01 ET

Pyng Medical Appoints Senior Sales Executive

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 12, 2007) - Pyng Medical Corp. (TSX VENTURE:PYT) is pleased to announce the appointment of David B. Bonar to the position of Vice President Sales and Marketing. Effective immediately, Mr. Bonar assumes full responsibility for all aspects of revenue generation, including effective deployment of distribution sales personnel, marketing programs and continued international market expansion.

"The scope of Mr. Bonar's responsibility is significant and supports Pyng's commitment to dramatic growth," said David Christie, President and Chief Executive Officer. "With unit growth of more than 50% in our current fiscal year, which closes at month-end, we are excited about the growth opportunities in our new fiscal year. David's excellent track record and knowledge of our industry will be instrumental in fueling continued growth and expansion of our business."

"Pyng has an excellent product in the FAST1™ and great plans for the future. With my experience and the strengths Pyng offers the market, I am confident we will continue to drive considerable growth, penetrate new markets, and continue to build world-class distribution channels for our products," said David Bonar.

About Pyng Medical Corp.

Pyng Medical Corp. is a world leader in intraosseous infusion with its proprietary award-winning FAST1™ Intraosseous Infusion System, the only device able to provide rapid sternal access and delivery of life saving fluids and drugs to the heart of critically injured patients within seconds. The FAST1™ is used extensively by the U.S. Department of Defense and by Emergency Medical Services around the globe.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Pyng Medical Corp.
    David Christie